BioCentury | Aug 8, 2020

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

NASDAQ debuts by Syncona gene therapy company Freeline and Checkmate, a cancer company co-founded by Art Krieg, pushed the year’s IPO haul to $14.7 billion, more than double the amount raised over the same period...
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

COO Franz-Werner Haas will become CureVac AG ’s permanent CEO, the mRNA vaccines company’s third this year. He has filled the role on an interim basis since mid-March. CEO Ingmar Hoerr took a leave of...
BioCentury | Jul 17, 2020

Bischofberger revisits Gilead castoff to pad Kronos’ pipeline of transcription modulators

New biomarker data for a clinical cancer therapy discontinued by Gilead prompted Kronos President and CEO Norbert Bischofberger to close a deal with his old company to bring the IP in-house to Kronos. The acquisition...
BioCentury | Jul 16, 2020

Relay’s IPO among the year’s largest for a biotech as others wait in wings

In a year when most new biotech listings have surpassed expectations, Relay’s upsized $400 million IPO is the second-largest yet for a therapeutics developer in 2020. The clinical developer of precision oncology therapies posted a...
BioCentury | Jul 10, 2020

After pouring into biotech in 2Q, will generalists stay or will they go?

Investors believe generalists are likely to remain overweight in healthcare until there’s confidence that the broader economy can start to recover. When that will happen and whether some generalists might stick around even after recovery...
BioCentury | Jun 13, 2020

With nearly $1B raised overnight, quartet of offerings underscore demand for biotech IPOs

Five biopharma IPOs raised nearly $1 billion this week, with four of the companies each raising more than $200 million and trading up at least 30% in their first day of trading. The strong debuts...
BioCentury | Jun 9, 2020

Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

Following last week’s IPO market performance, which saw three biotechs raise more than $740 million, a trio of preclinical companies are now preparing for their at bat. The IPO queue also gained five more companies...
BioCentury | Jun 6, 2020

Legend’s $424M NASDAQ offering pads 2020’s lead over prior years

Closely-watched CAR T company Legend raised more than $400 million Friday in the year's largest biotech IPO thus far. The deal helped push the total raised via life sciences IPOs to $6.2 billion, outpacing the...
BioCentury | Apr 30, 2020
Product Development

NIH competition to encourage COVID-19 diagnostic innovation, pad U.S. testing capacity

As dozens of leading biopharmas, research institutes and health agencies embrace precompetitive coalitions and master protocols to speed development of COVID-19 therapies and vaccines, NIH has created a competition to accelerate diagnostics. The organization today...
BioCentury | Mar 28, 2020
Product Development

COVID-19 diagnostic tech tableau

In the ramp-up of testing for COVID-19, two well-established technologies have divided the forefront: RT-PCR and immunoassays. The former tests for active infection by detecting viral RNA, while the latter can be used to detect...
Items per page:
1 - 10 of 505